Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2B Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer

NCT00609622 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00609622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00609622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2B Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2008
Completion date
July 31, 2011
Enrollment
191 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms